Advertisement

Tumorerkrankungen

  • Wolfgang Hiddemann
  • Andreas Neubauer
  • Kurt Possinger
  • Annette Dieing
  • Thomas Otto
  • Susanne Krege
  • Herbert Rübben
  • Volker Hanf
  • Rolf Kreienberg
  • Wilfried Eberhardt
  • Rolf D. Issels
  • Hanno Riess
  • Carsten Bokemeyer
  • Hannes Wandt
  • Else Heidemann
  • Christian Kurzeder
  • Dominique A. Zehnpfennig
  • Clemens-Martin Wendtner
  • Michael Hallek

Zusammenfassung

Man unterscheidet eine ganze Reihe verschiedener Klassen von Chemotherapeutika mit jeweils unterschiedlichem primärem Wirkungsansatz in der Zelle:
  • Antimetabolite, die als kompetitive Hemmer des Nukleinsäurestoffwechsels fungieren (z. B. Cytarabin, 5-Fluorouracil, Gemcitabin);

  • Alkylanzien (z. B. Cyclophosphamid, Ifosfamid, Busulfan);

  • natürlich vorkommende Antibiotika (z. B. Mitomycin, Bleomycin, Antrazykline);

  • Topoisomerase-I- und -II-Blocker (Topo I: Camptothecin; Topo II: Epipodophyllotoxine);

  • Pflanzenalkaloide:
    • Vincaalkaloide (z. B. Vincristin, Vinblastin, Vinorelbin)

    • Taxane (Paclitaxel, Docetaxel)

    • Epipodophyllinderivate (Etoposid, Teniposid);

  • Platinverbindungen (Cisplatin, Carboplatin, Oxaliplatin).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Adamson DJA, Thompson WD, Dawson AA, Bennett B, Haites NE (1995) p53 mutation and expression in lymphoma. British Journal of Cancer 72: 150–154Google Scholar
  2. Allan N, Richards S, Shepherd P et al. (1995) UK Medical Research Council randomized multicenter trial of interferon-alpha for chronic myeloid leukemia: Improved survival irrespective of cytogenetic response. Lancet 345: 1392Google Scholar
  3. Bergh J, Norberg T, Sjögren S, Lindgren A, Holmberg L (1995) Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particulary in relation to adjuvant systemic therapy and radiotherapy. Nature Medicine 1: 1029–1034PubMedGoogle Scholar
  4. Bosari S, Viale G, Bossi G, Maggioni M, Coggi C, Murray JJ, Lee AKC (1994) Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. Journal of National Cancer Institute 86: 681–687Google Scholar
  5. Colombat P, Salles G, Brousse N et al. (2001) Rituximab (antiCD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97: 101–106PubMedGoogle Scholar
  6. Czuczman MS, Grillo-Lopez AJ, White CA et al. (1999). Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17: 268–276PubMedGoogle Scholar
  7. Evan GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411: 342–348PubMedGoogle Scholar
  8. Feuring-Buske M, Kneba M, Unterhalt M et al. (2000) IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol 79: 493–500PubMedGoogle Scholar
  9. Gjertsen MK, Gaudernack G (1998) Mutated Ras peptides as vaccines in immunotherapy of cancer. Vox Sang 74 (Suppl 2): 489–495PubMedGoogle Scholar
  10. Grant S (1998) Ara-C: cellular and molecular pharmacology. Adv Cancer Res 72: 197–233PubMedGoogle Scholar
  11. Hamelin R, Laurent-Puig P, Olschwang S et al. (1994) Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 106: 42–48PubMedGoogle Scholar
  12. Hawkins DS, Demers GW, Galloway DA (1996) Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56: 892–898PubMedGoogle Scholar
  13. Hehlmann R, Heimpel H, Hasford J et al. (1994). Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogeneous leukemia. Blood 84: 4064–4077PubMedGoogle Scholar
  14. Huhn D, Herrmann R (2001). Medikamentöse Therapie maligner Erkrankungen. Urban amp Fischer, München Jena Lai WC, Bennett M (1998) DNA vaccines. Crit Rev Immunol 18: 449–484Google Scholar
  15. Lee DJ, Corr M, Carson DA (1998) Control of immune responses by gene immunization. Ann Med 30: 460–468PubMedGoogle Scholar
  16. Leukemia ICSGoCm (1994) Interferon alpha 2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330: 820–825Google Scholar
  17. Leukemia ICSGoCM (1998) Long-term follow up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. Blood 92: 1541–1548Google Scholar
  18. Ohnishi K, Ohno R, Tomonaga M et al. (1995) A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogeneous leukemia in chronic phase. Blood 86: 906–916PubMedGoogle Scholar
  19. Piro LD, White CA, Grillo-Lopez AJ (1999) Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 10: 655–661PubMedGoogle Scholar
  20. Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411: 380–384PubMedGoogle Scholar
  21. Rouby SE, Thomas A, Rosenberg CR, Potmesil M, Silber R, Newcomb EW (1993) p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82: 3452–3459Google Scholar
  22. Runnebaum IS, Nagarajan M, Bowman M, Soto D, Sukumar S (1991) Mutations in p53 as potential molecular markers for human breast cancer. Proceedings of the National Academy of Sciences USA 88: 10657–10661Google Scholar
  23. Schofield J, Robinson W, Murphy J, Rovira D (1994) Low doses of interferon-alpha are as effective as higher doses in inducing remissions and prologning survival in chronic myeloid leukemia. Ann Int Med 121: 736–744PubMedGoogle Scholar
  24. Schultze JL, Gribben JG, Nadler LM (1998) Tumor-specific adoptive T-cell therapy for CD40+ B-cell malignancies. Curr Opin Oncol 10: 542–547Google Scholar
  25. Sun XF, Carstensen JM, Zhang H, Stal O, Wingren S, Hatschek T, Nordenskjold B (1992) Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 340: 1369–1373PubMedGoogle Scholar
  26. Usami I, Kubota M, Bessho R, Kataoka A, Koishi S, Watanabe K, Sawada M, Lin YW, Akiyama Y, Furusho K (1998) Role of protein tyrosine phosphorylation in etoposide-induced apoptosis and NF-kappa B activation. Biochem Pharmacol 55: 185–191PubMedGoogle Scholar
  27. Wu GS, El-Deiry WS (1996) Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bd-2. Clin Cancer Res 2: 623–33PubMedGoogle Scholar
  28. Yamaguchi A, Kurosaka Y, Fushida S, Kanno M, Yonemura Y, Miwa K, Miyazaki I (1992) Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 70: 2778–2784Google Scholar
  29. Yuan ZM, Huang Y, Kraeft SK, Chen LB, Kharbanda S, Kufe D (1996) Interaction of cyclin-dependent kinase 2 and the Lyn tyrosine kinase in cells treated with 1-beta-D-arabinofuranosylcytosine. Oncogene 13: 939–946PubMedGoogle Scholar
  30. Kennedy MJ, Abeloff MD (1993) Management of locally recurrent breast cancer. Cancer 71: 2395–2409PubMedGoogle Scholar
  31. Konsensuskonferenz St. Gallen zur adjuvanten Therapie des Mammakarzinoms (2001) Vorläufige Empfehlungen. März 2001Google Scholar
  32. Mouridsen H, Gershanovich M, Sun Y et al. (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596–2606PubMedGoogle Scholar
  33. NIH, National Institutes of Health (2000) Consensus Development Conference Statement - adjuvant therapy for breast cancer.Google Scholar
  34. Possinger K, Schmoll HJ, Höffken K, Große Y (1999) Mammakarzinom. In: Schmoll HJ, Höffken K, Possinger K (Hrsg) Kompendium Internistische Onkologie, vol 2.: Springer, BerlinGoogle Scholar
  35. Altwein JE (1997) Prostatakarzinom. In: Rübben H (Hrsg) Uroonkologie, 2. Aufl. Springer, Berlin Heidelberg New York Tokyo, S 233–293Google Scholar
  36. Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC (1993) Heriditary prostate cancer: epidemiologic and clinical features. J Urol 150 (3): 797–802PubMedGoogle Scholar
  37. Hölzel D (1991) Epidemiologie des Prostatakarzinoms. Fortschr Med 109 (26): 521–525PubMedGoogle Scholar
  38. Mostofi FK, Sesterhenn J, Sobin LH (1980) Histologic typing of prostate tumors., WHO, Genua, No. 22Google Scholar
  39. Wirth M, Otto T, Rübben H (1998) Prostatakarzinom. Leitlinien der Deutschen Gesellschaft für Urologie. DGU-Mitteilungen 1998Google Scholar
  40. Wirth M. (1997) Therapie des lokal begrenzten Prostatakarzinom. In: Rübben H (Hrsg) Uroonkologie, 2. Aufl. Springer, Berlin Heidelberg New York Tokyo, S 294–400Google Scholar
  41. Castilla LH, Couch SJ, Erdos MR et al. (1994) Mutations in the BRCAI-Gene in families with early-onset breast and ovarian cancer. Mature Genet 8: 387–391Google Scholar
  42. Deutsche Krebsgesellschaft (1998/2000/2001) Qualitätssicherung in der Onkologie. Diagnose und Therapie maligner Erkrankungen. Kurzgefasste Interdisziplinäre Leitlinien 2000, S 301 ffGoogle Scholar
  43. Emons G, Ortmann O, Pahwa GS (1992) LH-RH agonists in the treatment of ovarian cancer. In: Höffken K (ed) Peptides in oncology I. LH-RH agonists and antagonists. Zuckschwerdt, München Bern Wien New York, p 55Google Scholar
  44. Grab D, Flock F, Stöhr I (2000) Classification or asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 77: 454–459PubMedGoogle Scholar
  45. Kuhn W (2001) Maligne Ovarialtumoren, 6. Aufl. W. Zuckschwerdt, München, S 24–31Google Scholar
  46. Kuhn W, Rutke S, Spathe K et al. (2001) Neo-adjuvant chemotherapy followed by tumor-debulking prolongs survival for patients with poor prognosis in ovarian cancer FIGO III c. Cancer: in pressGoogle Scholar
  47. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9: 389–393PubMedGoogle Scholar
  48. National Cancer Institute (1998) Screening for ovarian cancer. Tumorzentrum MünchenGoogle Scholar
  49. Rutke S, Spathe K, Schmalfeldt B, Graeff H, Kuhn W (2000) Primäre Chemotherapie beim fortgeschrittenen Ovarialkarzinom: Alternative zum radikalen operativen Tumordebulking? In: Schmid L, Wilmanns (eds) Praktische Onkologie. Akt Onkol Bd 109, Zuckschwerdt, München Bern Wien New York, pp 141–147Google Scholar
  50. Schelling, Kuhn, Gnirs et al. (1998) Kombination von Sonographie und farbkodierter Dopplersonographie zur Dignitätsbeurteilung von Ovarialtumoren. Geburtsh Frauenheilk 58: 382–387Google Scholar
  51. Scully RE, Sobin LH (1999) World Health Organisation (WHO). International histological classification of tumours. cal typing of ovarian tumours. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  52. Scully RE,Young RH, Clement Ph B (1998) Atlas of tumor pathology: Tumors of ovary, maldeveloped gonads, fallopian tube, and broad ligament. AFIP, Washington, D.C.Google Scholar
  53. Sobin LH, Wittekind C (1997) UICC, TNM Classification of malignant tumors, 5. Aufl. Wiley-Liss, New YorkGoogle Scholar
  54. Uzolds RS, Rubin SC, Thomas G, Robbuy S (1997) Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC (eds) Principles and practice of gynecologic oncology, 2nd edn. Lippencott Raven, Philadelphia, p 919Google Scholar
  55. ACOG, Commitee Opinion (1993) Estrogen replacement therapy and endometrial cancer. p 126Google Scholar
  56. Alberts DS, Mason-Liddil N (1989) The role of cisplatin in the management of advanced squamous cell cancer of the cervix. Semin Oncol 16 (Suppl 6): 66–78PubMedGoogle Scholar
  57. Atzinger A (1996) Bestrahlung beim Zervixkarzinom nach radikaler Operation: Welches Zielvolumen? Ist prophylaktische Bestrahlung der Paraaortalregion effektiv? Strahlenther Onkol 172: 229–230PubMedGoogle Scholar
  58. AWMF online (2001) Therapie der Adipositas. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Leitlinien der Deutschen Adipositas-GesellschaftGoogle Scholar
  59. Barakat RR, Park RC, Grigsby PW, Muss HD, Norris HJ (1997) Corpus: epithelial tumors. In: Hoskins et al. (eds) Principles and practice of gynecologic oncology. Lippincott Williams amp Wilkins, Philadelphia, pp 859 ffGoogle Scholar
  60. Berman ML, Ballon SC, Lagasse LD, Watring WG (1980) Prognosis and treatment of endometrial cancer. Am J Obstet Gynecol 136: 679–688PubMedGoogle Scholar
  61. Bischoff J (2000) Hormon-and Chemotherapie in der Rezidiv-und Palliativsituation. In: Tumorzentrum München: Manual Malignome des Corpus uteri. Zuckschwerdt, München, S 52–56Google Scholar
  62. Buckley SL, Tritz DM, Van Le L et al. (1996) Lymph node metastases and prognosis in patients with stage IA2 cervical cancer. Gynec Oncol 63: 4–9Google Scholar
  63. Burghardt E, Girardi F, Lahousen M et al. (1991) Microinvasive carcinoma of the uterine cervix ( International Federation of Gynecology and Obstetrics Stage OA ). Cancer 67: 1037Google Scholar
  64. Burghardt E, Ostör A, Fox H (1997) Editorial: The new FIGO definition of cervical cancer stage I a: a critique. Gynecol Oncol 65: 1–5PubMedGoogle Scholar
  65. Burghardt E, Webb MJ, Monaghan JM, Kindermann G (1993) Surgical gynecologic oncology. Thieme, Stuttgart New YorkGoogle Scholar
  66. Creasman WT (1995) New gynecologic cancer staging. Gynec Oncol 58: 157–158Google Scholar
  67. Delgado G, Bundy BN, Fowler WE et al. (1989) A prospective surgical pathological study of stage I squamous carcinoma of cervix: a Gynecologic Oncology Group study. Gynecol Oncol 35: 314PubMedGoogle Scholar
  68. Deutsche Krebsgesellschaft (2000) B22 Endometriumkarzinom. In: Qualitätssicherung in der Onkologie - Diagnose and Therapie maligner Erkrankungen. Kurzgefasste interdisziplinäre Leitlinien 2000. Zuckschwerdt, München, S 287 ffGoogle Scholar
  69. DiSaia PJ, Creasman WT (1997) Sarcoma of the uterus. In: Clinical gynecologic oncology, 5th ed. Mosby, St. Louis Baltimore Boston, pp 169–179Google Scholar
  70. Geisthövel F (1998) Obesity in female life–from molecular to clinical aspects. Zentralbl Gynakol 120 (5): 223–234PubMedGoogle Scholar
  71. Gershenson DM, Kavanagh JJ, Copeland LJ, Edwards CL, Stringer CA, Wharton JT (1987) Cisplatin therapy for disseminated mixed mesodermal sarcoma of the uterus. J Clin Oncol 5 (4): 618–621PubMedGoogle Scholar
  72. Glassburn JR (1981) Carcinoma of the endometrium. Cancer 48: 575–581PubMedGoogle Scholar
  73. Gusberg SB (1976) The evolution of modern treatment of corpus cancer. Cancer 38: 603–609PubMedGoogle Scholar
  74. Hatch KD, Gelder MS, Soong SJ, Baker VV, Shingleton HM (1990) Pelvic exenteration with low rectal anastomosis: survival, complications, and prognostic factors. Gynecol Oncol 38: 462–467PubMedGoogle Scholar
  75. Hoffmann W, Hirnle P, Clemens M et al. (1995) 13cis-retinoic acid in combination with interferon-alpha and concomitant irradiation in squamous cell carcinomas–toxicity and feasibility. Onkologie 18: 568–571Google Scholar
  76. Hoffmann W, Schiebe M, Clemens M, Souchon R, Hirnle P, Adamietz I, Bambert M (1997) 13cis-retinoic acid and interferon-alpha–irradiation in squamous cell carcinomas. Int J Cancer 70: 475–477Google Scholar
  77. IARC Monograph (1995) IARC monographs on the evaluation of carcinogenic risks to humans. Human papillomaviruses. TARC, Lyon, p 64Google Scholar
  78. Käser O (1983) Operative Möglichkeiten bei der Therapie des Endometriumkarzinoms. Gynäkologe 16: 99–103PubMedGoogle Scholar
  79. Kreienberg R (1998) Fortgeschrittene Stadien des invasiven Zer- vixkarzinoms–Operative Therapie. Onkologe 2: 142–152Google Scholar
  80. Kumar L, Grover R, Pokharel YH, Chander S, Kumar S, Singh R, Rath GK, Kochupillai V (1998) Neoadjuvant chemotherapy in locally advanced cervical cancer: two randomised studies. Aust N Z J Med 28 (3): 387–390PubMedGoogle Scholar
  81. Lacava JA, Leone BA, Machiavelli M et al. (1997) Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma. J Clin Oncol 15: 604–609PubMedGoogle Scholar
  82. Larson B, Silfverswärd C, Nilsson B, Petterson F (1990) Mixed Müllerian tumours of the uterus–prognostic factors: a clinical and histopathologic study of 147 cases. Radiother Oncol 17: 123–132PubMedGoogle Scholar
  83. Lawton F (1997) The management of endometrial cancer. Br J Obstet Gynaecol 104: 127–134PubMedGoogle Scholar
  84. Leminen A, Forss M, Lehtovirta P (1995) Endometrial adenocarcinoma with clinical evidence of cervical involvement: accuracy of diagnostic procedures, clinical course, and prognostic factors. Acta Obstet Gynecol Scand 74: 61–66PubMedGoogle Scholar
  85. Limper A, Rauthe G (2000) Nachsorge. In: Tumorzentrum München: Manual Malignome des Corpus uteri. Zuckschwerdt, München, S 57–69Google Scholar
  86. Lindner H, Likas P, Willgeroth F, Würschmidt F (2000) Radioonkologische Behandlung. In: Tumorzentrum München: Manual Malignome des Corpus uteri. Zuckschwerdt, München, S 39–46Google Scholar
  87. Lippman SM, Kavanagh JJ, Paredes-Espinoza M et al. (1992) 13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 84: 241–245Google Scholar
  88. Lotocki RJ, Copeland LJ, De Petrillo AD, Muirhead W (1983) Stage I endometrial carcinoma: treatment results in 835 patients. Am J Obstet Gynecol 146: 141–145PubMedGoogle Scholar
  89. Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL (1993) Prognostic factors in early stage uterine sarcoma–a GOG study. Cancer 71: 1702–1706PubMedGoogle Scholar
  90. Manchul L, Pintilie M, Lefebvre P, Fyles A, Kirkbride P, Levin W, Rawlings G (1994) Uterine sarcomas: prognostic factors and the role of radiation therapy. Int J Radiat Oncol Biol Phys 30 (Suppl 1): 284Google Scholar
  91. Möbus V, Kreienberg R (1998) Systemische Therapie des Zervixkarzinoms. Onkologe 4: 167–173Google Scholar
  92. Morris M, Eifel PJ, Lu J et al. (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340: 1137–43PubMedGoogle Scholar
  93. National Cancer Institute (1999) Concurrent chemoradiation for cervical cancer. Clinical announcement, Washington, D.C.Google Scholar
  94. Oberlechner E (2000) Adjuvante medikamentöse Therapie. In: Tumorzentrum München: Manual Malignome des Corpus uteri. Zuckschwerdt, München, S 47–51Google Scholar
  95. Park RC, Thigpen JT (1993) Chemotherapy in advanced and recurrent cervical cancer. A review. Cancer 71 (Suppl): 1446–1450PubMedGoogle Scholar
  96. Pecorelli S (1998) FIGO Annual report on the results of treatment in gynaecological cancer, 23rd ed. J Epidemiol Biostat 3: 1–168Google Scholar
  97. Peters III WA, Liu PY, Barrett II RJ et al. (2000) Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18: 1606–1613PubMedGoogle Scholar
  98. Pettersson F (1994) Annual report on the results of treatment in gynecological cancer. Radiumhemmet, StockholmGoogle Scholar
  99. Potter ME, Hatch KD, Potter MY, Shingleton HM, Baker VV (1989) Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin. Cancer 63: 1283–1286PubMedGoogle Scholar
  100. Rakar S, Kovacic J (1990) Prognostic factors in endometrial cancer. Eur J Gynaec Oncol 11: 233–235Google Scholar
  101. Sardi J, Sananes C, Giaroli AR et al. (1993) Results of a prospective randomized trial with neoadjuvant chemotherapy in stage IB, bulky, squamous carcinoma of the cervix. Gynecol Oncol 49: 156–165PubMedGoogle Scholar
  102. Scully RE, Bonfiglio T, Kurman RJ, Silverberg S, Williamson EJ (1994) World Health Organization international histological classification of tumors, histological typing of female genital tract tumors, 2nd ed. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  103. Shingleton HM, Thompson JD (1997) Cancer of the cervix. In: Rock JA, Thompson JD (eds) Te Linde’s operative gynecology. Lippincott-Raven, Philadelphia New York, pp 1413–1499Google Scholar
  104. Sutton GP, Blessing JA, Homesley HD, McGuire WP, Adcock L (1994) Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Cancer 73: 1453–1455PubMedGoogle Scholar
  105. Thomas GM (1999) Improved treatment for cervical cancer–concurrent chemotherapy and radiotherapy. Editorial. N Engl J Med 340, 1198–1200Google Scholar
  106. Thomas GM (2000) Concurrent chemotherapy and radiation for locally advanced cervical cancer: the new standard of care. Semin Radiat Oncol 10 (1): 44–50PubMedGoogle Scholar
  107. Toki N, Tsukamoto N, Kaku T, Toh N, Saito T, Kamura T, Matsukuma K, Nakano H (1991) Microscopic ovarian metastasis of the uterine cervical cancer. Gynecol Oncol 41: 46–51PubMedGoogle Scholar
  108. Wulf J, Flentje M (1998) Strahlentherapie des Zervixkarzinoms. Onkologe 4: 153–166Google Scholar
  109. Albeida SM (1998) Gene therapy for lung cancer and mesothelioma. Chest 111: 144S - 149SGoogle Scholar
  110. Antman KH, Pass HI, Schiff PB (2001) Management of Mesothehorns. In: De Vita VT Jr (ed) Cancer. Principles and Practice of Oncology, 6`h edn. Section 2. Lippincott, Williams and Wilkins, Philadelphia, pp 1943–1964Google Scholar
  111. Baas P, Murrer L, Zoetmulder FA et al. (1997) Photodynamic therapy as adjuvant therapy in surgically resected pleural malignancies. Br J Cancer 76: 819–826PubMedGoogle Scholar
  112. Byrne MJ, Davidson JA, Musk AW et al. (1999) Cisplatin and Gemcitabine treatment for malignant mesothelioma. A phase-II study. J Clin Oncol 17: 25Google Scholar
  113. Chahinian GA, Pass HI (2000) Malignant mesothelioma. In: Bast RC, Kufe DW, Pollock RE et al. (eds) Cancer Medicine, 5th edn. B.C. Decker, News York, pp 1293–1312Google Scholar
  114. Eberhardt W, Dienemann H, Stüben G (2002) Malignes Mesotheliom. In: Seeber S, Schütte J (eds) Therapiekonzepte Onkologie. Springer, Berlin Heidelberg New York Tokyo (im Druck)Google Scholar
  115. Giaccone G, Baas P (1999) Mesotheliomas. In: Raghavan D, Brecher ML, Johnson DH et al. (eds) Textbook of uncommon cancer, 2“ edition, pp 523–535. Wiley, Chichester New York Weinheim Brisbane Singapore TorontoGoogle Scholar
  116. Peto J, Decarli A, La Vecchia C et al. (1999) The European mesothelioma epidemic. Br J Cancer 79: 666–672PubMedGoogle Scholar
  117. Rusch VW (1995) A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 108: 1122PubMedGoogle Scholar
  118. Sugarbaker DJ, Garcia JP, Richards et al. 1996 ) Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surgery 224: 288Google Scholar
  119. Testa JR, Pass HI, Carbone M (2001) Molecular biology of mesothelioma. In: De Vita (ed) Cancer. Principles and Practice of Oncology. 6th edition. Section 2. Lippincott, Williams and Wilkins, Philadelphia, pp 1937–1942Google Scholar
  120. Blay JY, Bouhour D, Ray-Coquard I, Dumontet C, PhilipT, Biron P (2000) High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft-tissue sarcoma in adults. J Clin Oncol 3643–3650Google Scholar
  121. Coindre JM, Terrier P, Binh Bui N, Bonichon F, Collin F, Le Doussal V et al. (1996) Prognostic factors in adult patients with locally controlled soft tissue sarcoma: a study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 14: 869–877PubMedGoogle Scholar
  122. Graadt van Roggen JF, van Velthuyaen MLF, Hogendoorn PCW (2001) The histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol 54: 96–103PubMedGoogle Scholar
  123. Guillou L, Coindre JM, Bonichon F, Binh Bui N, Terrier P, Collin F, et al. (1997) Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group Grading Systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997; 15: 350–362Google Scholar
  124. Heslin MJ, Lewis JJ, Nadler E, Newman E, Woodruff JM, Casper ES, et al. (1997) Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management. J Clin Oncol 15: 2832–2839PubMedGoogle Scholar
  125. Issels R, Abdel-Rahman S, Wendtner CM, Falk MH, Kurze V, Sauer H et al. (2001) Neoadjuvant chemotherapy combined with regional hyperthermie (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study. Eur J Cancer 37: 1599–1608PubMedGoogle Scholar
  126. Issels R (1999) Empfehlungen zur Diagnostik, Therapie und Nachsorge. Knochentumoren/Weichteilsarkome, 3. Aufl. Schriftenreihe, Tumorzentrum MünchenGoogle Scholar
  127. Koscielniak E, Harms D, Henze G, Jürgens H, Gadner H, Herbst M, et al. (1999) Results of treatment for soft tissue sarcoma in childhood and adolescence: A final report of the German Cooperative Soft Tissue Sarcoma Group CWS-86. J Clin Oncol 17: 3706–3719PubMedGoogle Scholar
  128. Trovik CS, Bauer HCF, Alvegard TA, Anderson H, Blomqvist C, Berlin Ö et al. (2000) Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register. Eur J Cancer 36: 710–716Google Scholar
  129. Wendtner CM, Abdel-Rahman S, Baumert J, Falk MH, Krych M, Sand M et al. (2001) Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia. Eur J Cancer 37: 1609–1616PubMedGoogle Scholar
  130. Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL et al. (1998) Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 16: 197–203PubMedGoogle Scholar
  131. Brizel DM, Albers MA, Fisher SR (1998) Hyperfractionated irradiation with and without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338: 1798–1804PubMedGoogle Scholar
  132. Budach V, Budach W (2001) Sequentielle und simultane Radiochemotherapie bei lokal fortgeschrittenen Kopf-Hals-Tumoren. Onkologe 5: 533–549Google Scholar
  133. Budach W, Belka C, Budach V (2001) Konventionell und unkonventionell fraktionierte alleinige Strahlentherapie bei Plattenepithelkarzinomen des Pharynx und Larynx. Onkologe 5: 533–549Google Scholar
  134. El-Sayed S, Nelson N (1996) Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: A meta-analysis of prospective and randomized trials. J Clin Oncol 14: 838–847Google Scholar
  135. Ganly I, Kaye SB (2000) Recurrent squamous-cell carcinoma of the head and neck: overview of current and future prospects. Ann Oncol 11: 11–26PubMedGoogle Scholar
  136. Jacobs C, Lyman G, Velez-Garcia E (1992) A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10: 257–263PubMedGoogle Scholar
  137. Jeremic B, Shibamoto Y, Milicic J (2000) Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 18: 1458–1464PubMedGoogle Scholar
  138. List MA, Haraf D, Stracks J, Stenson B, Brockstein M, Kies F, Rosen E, Vokes EE (2000) Quality of life (QOL) performance in head and neck cancer (HNC): comparison between paclitaxelbased (P-CT/XRT) and cisplatin-based (C-CT/XRT) concomitant chemoradiotherapy regimens. Proc Am Soc Clin Oncol 19: 412a (A1625)Google Scholar
  139. Pignon JP, Bourhis J, Domenge C et al. (2000) Chemotherapy added to local treatment for head and neck squamous cell carcinoma: three metaanalyses of updated individual data. MACH-NC collaborative group. Lancet 355: 949–955Google Scholar
  140. Posner MR, Colevas D (2000) The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. Sem Oncol 27: 13–24Google Scholar
  141. Schantz SP, Sessions RB, Harrison LB (1997) Cancer of the head and neck. In: De Vita VT, Helklmann S, Rosenberg SA (eds) Principles and practices of oncology, 5`h edn. Lippincott, Philadelphia PA, pp 741–801Google Scholar
  142. Vokes EE, Athanasiadis I (1996) Chemotherapy for squamous cell carcinoma of head and neck: the future is now. Ann Oncol 7: 15–29PubMedGoogle Scholar
  143. Wendt TG, Grabenhauer GG, Rödel CM (1998) Simultaneous radiochemohtherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 16: 1318–1324PubMedGoogle Scholar
  144. Wust P, Stahl H, Dieckmann K (1996) Local hyperthermia of N2/N3 cervical lymph node metastases: correlation of technical/thermal parameters and response. Int J Radiat Oncol Biol Phys 34 (3): 635–646PubMedGoogle Scholar
  145. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN (1995) Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 13: 2094–2103PubMedGoogle Scholar
  146. Ayoub JP, Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL (1998) Unknown primary tumors metastatic to liver. J Clin Oncol 16: 2105–2112PubMedGoogle Scholar
  147. Bokemeyer C (1999) Tumormetastasen bei unbekanntem Primärtumor. In: Thiemes Innere Medizin. Thieme, Stuttgart New York, S 1022–1027Google Scholar
  148. Greco FA, Erland JB, Morrissey LH (2000) Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 11: 211–215Google Scholar
  149. Hainsworth JD, Greco FA (1993) Treatment of patients with cancer of an unknown primary site. N Engl J Med 329: 257–263PubMedGoogle Scholar
  150. Hainsworth JD, Erland JB, Kalman LA, Schreeder MT, Greco FA (1997) Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol 15: 2385–2393PubMedGoogle Scholar
  151. Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL (1999) Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 5: 3403–3410PubMedGoogle Scholar
  152. Hübner G, Wildfang I, Schmoll HJ (1999) Metastasen bei unbekanntem Primärtumor–CUP-Syndrom. In: Schmoll HJ, Höffken K, Possinger K (Hrsg) Kompendium Internistische Onkologie, 3. Aufl. Springer, Berlin Heidelberg New York Tokyo, S 2137–2182Google Scholar
  153. Kath R, Höffken K (1998) Metastasierender Tumor mit unklarer Primärlokalisation. In: Heidemann E, Bokemeyer C (Hrsg) Solide Tumoren, 2. Aufl. Zuckschwerdt, München Bern Wien New York, S 203–209Google Scholar
  154. Muir C (1995) Cancer of unknown primary site. Cancer 75 (Suppl): 353–356PubMedGoogle Scholar
  155. Weinländer G, Scheithauer W (1998) Diagnostische und therapeutische Prinzipien bei Karzinomen unklarer Primärlokalisation. Onkologie 21: 67–71Google Scholar
  156. American Society of Clinical Oncology (1994) Recommendations for the use of hematopoietic colony-stimmulating factors: evidence-based, clinical practice guidelines. J Clin Oncology 12 (11): 2471–2508Google Scholar
  157. Antiemetic Subcommitee of the Multinational Association of Supportive Care in Cancer (MASCC) (1998) Prevention of chemotherapy–and radiotherapy–induced emesis: Results of the Perugia Consensus Conference. Ann Oncol 9: 811–819Google Scholar
  158. Bunte S, Ludwig WD (1994) Rationale Substitution mit Blut-und Blutbestandteilkonserven. Dtsch Med Wschr 119: 1555–1561PubMedGoogle Scholar
  159. Freifeld A, Marchigiani D, Walsh T (1999) A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 341: 305–311PubMedGoogle Scholar
  160. Italian Group For Antiemetic Research (2000) Dexamethasone alone or in combination with ondosetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 342: 1554–1559Google Scholar
  161. Link H, Blumenstengel K, Bohme A, Comely O, Kellner O, Nowrousian MR et al. (1999) Antimikrobioelle Therapie von unerklärtem Fieber bei Neutropenie; Standardempfehlungen der Arbeitsgemeinschaft Infektiologie in der Hämatologie und Onkologie der Deutschen Gesellschaft für Hämatologie und Onkologie. Dtsch Med Wschr 124 (Suppl 1): 3–8Google Scholar
  162. Maschmeyer G, Beinert T, Buchheidt D, Einsele H, Holler E (1999) Diagnosis and therapy of lung infiltrates in febrile neutropenic patients. Standard recommendations of the Work Group of Infections in Hematology and Oncology of the German Association of Hematology and Oncology. Dtsch Med Wschr 124 (Suppl 1): 18–23Google Scholar
  163. Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328: 1323–1332PubMedGoogle Scholar
  164. Rolston KVI (1998) Risk assessment and risk-based therapy in febrile neutropenic patients. Eur J Clin Microbiol Infect Dis 17: 461–463PubMedGoogle Scholar
  165. Wandt H, Frank M, Ehninger G et al. (1998) Safety and cost effectiveness of a 10x109/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 109/L Trigger: A prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 91 (10): 3601–3606PubMedGoogle Scholar
  166. Berensen JR, Lichtenstein A, Porter L (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334: 488–493Google Scholar
  167. Deutsche Interdisziplinäre Vereinigung für Schmerztherapie (1999) Leitlinie zur Tumorschmerztherapie. Tumor Diagnostik und Therapie 20: 105–129Google Scholar
  168. Cleeland CS, Gonin R, Hatfield AK (1994) Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 330: 592–596PubMedGoogle Scholar
  169. Hortobagyi GN, Theriault RL, Porter L (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335: 1785–1791PubMedGoogle Scholar
  170. Latreille Jet al. (1994) Aredia infusion in breast cancer: A randomized phase III trial to assess delay in progression of bone metastases. Proc Amer Soc Clin Oncol 13: 78Google Scholar
  171. Levy MH (1996) Pharmacologie treatment of cancer pain. N Engl J Med 335: 1124–1132PubMedGoogle Scholar
  172. Anderson WF (1998) Human gene therapy. Nature 392: 25–30PubMedGoogle Scholar
  173. Bendandi M, Gocke CD, Kobrin CB et al. (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma [see comments]. Nat Med 5: 1171–1177PubMedGoogle Scholar
  174. Bonini C, Ferrari G, Verzeletti S et al. (1997) HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia [see comments]. Science 276: 1719–1724PubMedGoogle Scholar
  175. Boon T, Coulie PG, Van den Eynde B (1997) Tumor antigens recognized by T cells. Immunol Today 18: 267–268PubMedGoogle Scholar
  176. Buhmann R, Nolte A, Westhaus D, Emmerich B, Hallek M (1992) CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood 93: 1992–2002Google Scholar
  177. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550–1552PubMedGoogle Scholar
  178. Dranoff G, Jaffee E, Lazenby A et al. (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539–3543PubMedGoogle Scholar
  179. Druker B, Talpaz M, Resta D et al. (2001) Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031–1037PubMedGoogle Scholar
  180. Folkman J (1996) Tumor angiogenesis. Cancer medicine. Williams amp Wilkins, BaltimoreGoogle Scholar
  181. Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM (1994) Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84: 3261–3282PubMedGoogle Scholar
  182. Hesdorffer C, Ayello J, Ward M et al. (1998) Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 16: 165–172PubMedGoogle Scholar
  183. Keene JA, Forman J (1982) Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med 155: 768–782PubMedGoogle Scholar
  184. King CA, Spellerberg MB, Zhu D et al. (1998) DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 4: 1281–1286PubMedGoogle Scholar
  185. Nestle FO, Alijagic S, Gilliet M et al. (1998) Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 4: 328–332PubMedGoogle Scholar
  186. Prehn RT (1957) Immunity to Methylcholanthrene-induced sarcomas. J Nat Cancer Inst 18: 769–778PubMedGoogle Scholar
  187. Romani N, Gruner S, Brang D et al. (1994) Proliferating dendritic cell progenitors in human blood. J Exp Med 180: 83–93PubMedGoogle Scholar
  188. Schuler M, Rochlitz C, Horowitz JA et al. (1998) A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther 9: 2075–2082PubMedGoogle Scholar
  189. Stevenson FK, Zhu D, King CA, Ashworth LJ, Kumar S, Hawkins RE (1995) Idiotypic DNA vaccines against B-cell lymphoma. Immunol Rev 145: 211–228PubMedGoogle Scholar
  190. Townsend SE, Allison JP (1993) Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259: 368–370PubMedGoogle Scholar
  191. Trojan A, Schultze JL, Witzens M et al. (2000) Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med 6: 667–672PubMedGoogle Scholar
  192. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM (1999) The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10: 673–679PubMedGoogle Scholar
  193. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ (2000) CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96: 2917–2924PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • Wolfgang Hiddemann
  • Andreas Neubauer
  • Kurt Possinger
  • Annette Dieing
  • Thomas Otto
  • Susanne Krege
  • Herbert Rübben
  • Volker Hanf
  • Rolf Kreienberg
  • Wilfried Eberhardt
  • Rolf D. Issels
  • Hanno Riess
  • Carsten Bokemeyer
  • Hannes Wandt
  • Else Heidemann
  • Christian Kurzeder
  • Dominique A. Zehnpfennig
  • Clemens-Martin Wendtner
  • Michael Hallek

There are no affiliations available

Personalised recommendations